GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Debt-to-EBITDA

BioAdaptives (BioAdaptives) Debt-to-EBITDA : -0.34 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioAdaptives's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.33 Mil. BioAdaptives's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. BioAdaptives's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.96 Mil. BioAdaptives's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioAdaptives's Debt-to-EBITDA or its related term are showing as below:

BDPT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.25   Med: -0.68   Max: -0.01
Current: -0.63

During the past 9 years, the highest Debt-to-EBITDA Ratio of BioAdaptives was -0.01. The lowest was -9.25. And the median was -0.68.

BDPT's Debt-to-EBITDA is ranked worse than
100% of 1430 companies
in the Consumer Packaged Goods industry
Industry Median: 2.125 vs BDPT: -0.63

BioAdaptives Debt-to-EBITDA Historical Data

The historical data trend for BioAdaptives's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives Debt-to-EBITDA Chart

BioAdaptives Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -9.25 -0.78 -0.68 -0.72 -0.63

BioAdaptives Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 -0.38 -1.04 1.85 -0.34

Competitive Comparison of BioAdaptives's Debt-to-EBITDA

For the Packaged Foods subindustry, BioAdaptives's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAdaptives's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioAdaptives's Debt-to-EBITDA falls into.



BioAdaptives Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioAdaptives's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.329 + 0) / -0.521
=-0.63

BioAdaptives's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.329 + 0) / -0.96
=-0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioAdaptives  (OTCPK:BDPT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioAdaptives Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioAdaptives's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAdaptives (BioAdaptives) Business Description

Traded in Other Exchanges
N/A
Address
2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128
BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.
Executives
Richard Chiang other: Previous Officer and Director 460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling director 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc. 10 percent owner 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling director, officer: Pres, CEO, Secretary, CFO 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128

BioAdaptives (BioAdaptives) Headlines

From GuruFocus

BioAdaptives Sponsors COVID-19 Long Hauler Survey

By GuruFocusNews GuruFocusNews 06-22-2022

BioAdaptives Sponsors COVID-19 Long Hauler Survey

By GuruFocusNews GuruFocusNews 06-12-2022